A real-world pharmacovigilance study and pharmacological analysis of sulfasalazine based on the FDA adverse event reporting system (FAERS) database
This study revealed potential new AEs resulting from sulfasalazine, and further studies are needed to confirm these new AEs.
Authors
- Bufu Tang (ORCID: https://orcid.org/0000-0003-3525-4433)
- Hongjie Fan (ORCID: https://orcid.org/0000-0002-3001-0133)
- Peng Luo (ORCID: https://orcid.org/0000-0002-8215-2045)
- Zhijun Shen
- Qing Li (ORCID: https://orcid.org/0000-0002-4538-9414)
- Jian Zhang (ORCID: https://orcid.org/0000-0002-6558-791X)
- Zhao Xie (ORCID: https://orcid.org/0000-0001-9834-4730)
- Dandan Guo (ORCID: https://orcid.org/0000-0002-3324-5851)
- Shuai Fu (ORCID: https://orcid.org/0000-0003-1810-2876)
- Lvdan Deng
- Ling Wang (ORCID: https://orcid.org/0000-0002-5176-7469)
- Na Hang
Institutions
- Dalian Medical University (CN)
- Fudan University (CN)
- First Affiliated Hospital of Dalian Medical University (CN)
- Huazhong University of Science and Technology (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1080/14740338.2025.2488241
- Citations
- 2
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 2.61
Funders
- National Natural Science Foundation of China